The purinergic system in allotransplantation

American Journal of Transplantation

Volumn 14, Issue 3, 2014, Pages 507-514

  Vergani, A ^a,b   Tezza, S ^a   Fotino, C ^c   Visner, G ^a   Pileggi, A ^c   Chandraker, A ^d   Fiorina, P ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MIAMI   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ATP; P2X7R; purinergic system; rejection

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y14 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PURINERGIC RECEPTOR; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; APOPTOSIS; ENTERITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION; VASCULITIS;

ATP; P2X7R; PURINERGIC SYSTEM; REJECTION;

ANIMALS; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; RECEPTORS, PURINERGIC; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84896739530     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12567     Document Type: Review

References (68)

1. Kaplan BL., The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 2013; 137: 365-374.
2. Eltzschig HK, Sitkovsky MV, Robson SC., Purinergic signaling during inflammation. N Engl J Med 2012; 367: 2322-2333.
3. Junger WG., Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011; 11: 201-212.
4. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B., The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol 2001; 166: 7172-7177.
5. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC., Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
6. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F., Increased level of extracellular ATP at tumor sites: In vivo imaging with plasma membrane luciferase. PLoS ONE 2008; 3: e2599.
7. North RA., Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013-1067.
8. Corriden R, Insel PA., Basal release of ATP: An autocrine-paracrine mechanism for cell regulation. Sci Signal 2010; 3: re1.
9. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-552.
10. Woehrle T, Yip L, Elkhal A, et al. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 2010; 116: 3475-3484.
11. Chekeni FB, Elliott MR, Sandilos JK, et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010; 467: 863-867.
12. Di Virgilio F, Chiozzi P, Ferrari D, et al. Nucleotide receptors: An emerging family of regulatory molecules in blood cells. Blood 2001; 97: 587-600.
13. Wang L, Jacobsen SE, Bengtsson A, Erlinge D., P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5: 16.
14. Woehrle T, Yip L, Manohar M, et al. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptors. J Leukoc Biol 2010; 88: 1181-1189.
15. Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS., Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: Evidence for nonfunctional P2X(7) receptors. Am J Physiol Cell Physiol 2000; 279: C1189-C1197.
16. Aswad F, Kawamura H, Dennert G., High sensitivity of CD4+ CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: A role for P2X7 receptors. J Immunol 2005; 175: 3075-3083.
17. Sluyter R, Barden JA, Wiley JS., Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res 2001; 304: 231-236.
18. Chen JR, Gu BJ, Dao LP, Bradley CJ, Mulligan SP, Wiley JS., Transendothelial migration of lymphocytes in chronic lymphocytic leukaemia is impaired and involved down-regulation of both L-selectin and CD23. Br J Haematol 1999; 105: 181-189.
19. Wiley JS, Dao-Ung LP, Gu BJ, et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: A molecular study. Lancet 2002; 359: 1114-1119.
20. Ferrari D, La Sala A, Chiozzi P, et al. The P2 purinergic receptors of human dendritic cells: Identification and coupling to cytokine release. FASEB J 2000; 14: 2466-2476.
21. Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: Modulatory roles in inflammation and immune responsiveness. Nat Med 2002; 8: 358-365.
22. Coutinho-Silva R, Ojcius DM, Gorecki DC, et al. Multiple P2X and P2Y receptor subtypes in mouse J774, spleen and peritoneal macrophages. Biochem Pharmacol 2005; 69: 641-655.
23. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J., Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14: 1583-1589.
24. Coutinho-Silva R, Correa G, Sater AA, Ojcius DM., The P2X(7) receptor and intracellular pathogens: A continuing struggle. Purinergic Signal 2009; 5: 197-204.
25. Jamieson SE, Peixoto-Rangel AL, Hargrave AC, et al. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun 2010; 11: 374-383.
26. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
27. Somers GR, Hammet FM, Trute L, Southey MC, Venter DJ., Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Lab Invest 1998; 78: 1375-1383.
28. Schnurr M, Then F, Galambos P, et al. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol 2000; 165: 4704-4709.
29. Clifford EE, Martin KA, Dalal P, Thomas R, Dubyak GR., Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5′-nucleotidase in myeloid leukocytes. Am J Physiol 1997; 273 (3 Pt 1): C973-C987.
30. Goepfert C, Sundberg C, Sevigny J, et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 2001; 104: 3109-3115.
31. Chen BC, Lin WW., Pyrimidinoceptor potentiation of macrophage PGE(2) release involved in the induction of nitric oxide synthase. Br J Pharmacol 2000; 130: 777-786.
32. Zhou Q, Yan J, Putheti P, et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transplant 2009; 9: 2303-2311.
33. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC., CD39 and control of cellular immune responses. Purinergic Signal 2007; 3: 171-180.
34. Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL., Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 2013; 122: 9-18.
35. Adrian K, Bernhard MK, Breitinger HG, Ogilvie A., Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochim Biophys Acta 2000; 1492: 127-138.
36. Heyn J, Ledderose C, Hinske LC, et al. Adenosine A2A receptor upregulation in human PMNs is controlled by miRNA-214, miRNA-15, and miRNA-16. Shock 2012; 37: 156-163.
37. Majumdar S, Aggarwal BB., Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001; 167: 2911-2920.
38. Conigrave AD, Fernando KC, Gu B, et al. P2Y(11) receptor expression by human lymphocytes: Evidence for two cAMP-linked purinoceptors. Eur J Pharmacol 2001; 426: 157-163.
39. Hofer M, Weiterova L, Vacek A, Znojil V, Pospisil M, Vacha J., Elevation of extracellular adenosine mobilizes haematopoietic progenitor cells and granulocytes into peripheral blood and enhances the mobilizing effects of granulocyte colony-stimulating factor. Eur J Haematol 2003; 71: 204-210.
40. Panther E, Idzko M, Herouy Y, et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J 2001; 15: 1963-1970.
41. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, Hauschildt S., Regulation of adenosine receptor subtypes during cultivation of human monocytes: Role of receptors in preventing lipopolysaccharide-triggered respiratory burst. Infect Immun 2004; 72: 1349-1357.
42. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M., Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004; 173: 21-24.
43. Zhang JG, Hepburn L, Cruz G, Borman RA, Clark KL., The role of adenosine A2A and A2B receptors in the regulation of TNF-alpha production by human monocytes. Biochem Pharmacol 2005; 69: 883-889.
44. Vergani A, Tezza S, D'Addio F, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 2013; 127: 463-475.
45. Vergani A, Fotino C, D'Addio F, et al. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 2013; 62: 1665-1675.
46. Wilhelm K, Ganesan J, Muller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010; 16: 1434-1438.
47. Schenk U, Frascoli M, Proietti M, et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011; 4: ra12.
48. Schenk U, Westendorf AM, Radaelli E, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008; 1: ra6.
49. Daniel C, Wennhold K, Kim HJ, von Boehmer H., Enhancement of antigen-specific Treg vaccination in vivo. Proc Natl Acad Sci USA 2010; 107: 16246-16251.
50. Dormond O, Dufour M, Seto T, Bruneau S, Briscoe DM., Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol 2012; 73: 1261-1268.
51. Riegel AK, Faigle M, Zug S, et al. Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood 2011; 117: 2548-2555.
52. Grbic DM, Degagne E, Langlois C, Dupuis AA, Gendron FP., Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. J Immunol 2008; 180: 2659-2668.
53. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10: 2586-2595.
54. Fiorina P, Ansari MJ, Jurewicz M, et al. Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol 2006; 17: 716-723.
55. Guckelberger O, Sun XF, Sevigny J, et al. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 2004; 91: 576-586.
56. Laubach VE., Therapeutic potential for CD39 in renal transplantation: There is hope. Am J Transplant 2010; 10: 2567-2568.
57. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP., Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113: 224-232.
58. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007; 21: 2863-2873.
59. Hart ML, Gorzolla IC, Schittenhelm J, Robson SC, Eltzschig HK., SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol 2010; 184: 4017-4024.
60. Colgan SP, Eltzschig HK., Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Annu Rev Physiol 2012; 74: 153-175.
61. Hasegawa T, Bouis D, Liao H, Visovatti SH, Pinsky DJ., Ecto-5′ nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res 2008; 103: 1410-1421.
62. Li L, Huang L, Ye H, et al. Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury. J Clin Invest 2012; 122: 3931-3942.
63. Hart ML, Much C, Gorzolla IC, et al. Extracellular adenosine production by ecto-5′-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008; 135: 1739-1750.e3.
64. Zimmerman MA, Tak E, Ehrentraut SF, et al. Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion. Hepatology 2013; doi: 10.1002/hep.26505 [Epub ahead of print].
65. Zimmerman MA, Grenz A, Tak E, et al. Signaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver. Proc Natl Acad Sci USA 2013; 110: 12012-12017.
66. Glas R, Sauter NS, Schulthess FT, Shu L, Oberholzer J, Maedler K., Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival. Diabetologia 2009; 52: 1579-1588.
67. Mendolicchio GL, Zavalloni D, Bacci M, et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2011; 9: 373-382.
68. Maffi P, Bertuzzi F, De Taddeo F, et al. Kidney function after islet transplant alone in type 1 diabetes: Impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007; 30: 1150-1155.